EUVIMEDEUVIMED entdecken
Open Access

HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice

Sei Morinaga, Kohei Mizuta, Byung Mo Kang, Qinghong Han, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya und 2 weitere

In Vivo · 2025

DOI: 10.21873/invivo.13931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Sei Morinaga und 13 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Ketones, Drug Resistance, Neoplasm, Furans, Methionine. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Eribulin is a microtubule inhibitor used in the treatment of various malignancies, including soft-tissue sarcoma. However, the development of eribulin resistance is a recalcitrant clinical problem. The present study demonstrates that super eribulin-resistant HT1080 human fibrosarcoma cells become highly malignant but can be eradicated synergistically by the combination of eribulin and methionine restriction in nude mice. MATERIALS AND METHODS: The cell viability of parental HT1080 cells and super eribulin-resistant HT1080 was determined following eribulin treatment using the WST-8 reagent. In vitro invasion assays, comprising wound-healing of cell monolayers, were performed to determine the degree of malignancy. Tumor growth to determine malignancy and tumor-growth sensitivity to eribulin, or a methionine-restricted diet, or their combination were analyzed in athymic nude mice. RESULTS: The IC50 of eribulin for parental HT1080 cells was 0.15 nM, whereas for super eribulin-resistant HT1080 cells, the IC50 of eribulin was 18 nM, a 120-fold increase. Super eribulin-resistant HT1080 cells had a more rapid wound-healing closure rate in vitro than their parental HT1080 cells, indicating increased malignancy. Similarly, in vivo, untreated super eribulin-resistant HT1080 tumors grew faster than parental HT1080 tumors, confirming their high malignancy. The combination of a methionine-restricted diet and eribulin synergistically arrested super eribulin-resistant HT1080 tumors. Methionine restriction sensitized these highly resistant and malignant cells to eribulin. CONCLUSION: Methionine restriction combined with eribulin represents a promising strategy to effectively treat eribulin-resistant high-malignancy fibrosarcoma, that can be immediately applied to the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetonesDrug Resistance, NeoplasmFuransMethionineFibrosarcomaHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorMice, NudeCell SurvivalCell ProliferationDisease Models, AnimalAntineoplastic AgentsPolyether Polyketides

Stichwörter der Autor:innen

HT1080Hoffman effecteribulinfibrosarcomahigh malignancymethionine addictionmethionine restrictionnude micesuper eribulin-resistancesynergy

Substanzen

eribulinKetonesFuransMethionineAntineoplastic AgentsPolyether Polyketides

Autor:innen und Institutionen

  • AntiCancer Inc., San Diego, CA, U.S.A.
  • Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
  • AntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Zitieren

APA

Morinaga, S., Mizuta, K., Kang, B. M., Han, Q., Bouvet, M., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Higuchi, T., Tsuchiya, H., Demura, S., & Hoffman, R. M. (2025). HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice. In Vivo. https://doi.org/10.21873/invivo.13931

Vancouver

Morinaga S, Mizuta K, Kang BM, Han Q, Bouvet M, Yamamoto N, et al. HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice. In Vivo. 2025. doi:10.21873/invivo.13931

BibTeX
@article{Morinaga2025,
  author = {Morinaga, Sei and Mizuta, Kohei and Kang, Byung Mo and Han, Qinghong and Bouvet, Michael and Yamamoto, Norio and Hayashi, Katsuhiro and Kimura, Hiroaki and Miwa, Shinji and Igarashi, Kentaro and Higuchi, Takashi and Tsuchiya, Hiroyuki and Demura, Satoru and Hoffman, Robert M},
  title = {HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.13931}
}
Kostenlos starten →